Marksans Pharma Limited · MARKSANS
Every Marksans Pharma Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
25results judged
1read right
0read wrong
4flat / no call
20unread
52%beat the market
+2.5%avg vs market, 10d
4.6%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| strong | 1 | 0 | 0 | 1 | — | -0.2% | |
| favourable | 1 | 0 | 0 | 1 | — | -1.5% | |
| neutral | 1 | 0 | 0 | 1 | — | +4.7% | |
| unfavourable | 1 | 0 | 0 | 1 | — | -0.4% | |
| weak | 1 | 1 | 0 | 0 | 100% | -9.5% | |
| unread | 20 | 0 | 0 | 0 | — | +3.4% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
25 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 12 Aug Q1FY27 | — | unread | +6.5% | +4.3% | +5.7% | +16% | no figures |
|
› |
| 26 May Q4FY26 | strong | neutral | — | -3.1% | -0.2% | +43% | no figures |
|
› |
| 5 Feb Q3FY26 | unfavourable | neutral | +3.9% | -0.7% | -0.4% | -2% | no figures |
|
› |
| 13 Nov Q2FY26 | favourable | neutral | +3.6% | -0.2% | -1.5% | +13% | no figures |
|
› |
| 12 Aug Q1FY26 | weak | right | -4.4% | -9.7% | -9.5% | -28% | no figures |
|
› |
| 19 May Q4FY25 | neutral | neutral | -1.3% | +3.1% | +4.7% | +14% | no figures |
|
› |
| 11 Feb Q3FY25 | — | unread | -0.9% | -15.8% | -13.5% | -15% | no figures |
|
› |
| 12 Nov Q2FY25 | — | unread | +2.6% | +11.7% | +11.6% | +1% | no figures |
|
› |
| 14 Aug Q1FY25 | — | unread | +11.1% | +24.5% | +20.3% | +15% | no figures |
|
› |
| 30 May Q4FY24 | — | unread | -0.5% | +9.7% | +5.4% | -6% | no figures |
|
› |
| 13 Feb Q3FY24 | — | unread | +2.6% | -3.3% | -4.3% | -2% | no figures |
|
› |
| 10 Nov Q2FY24 | — | unread | +11.5% | +15.2% | +12.7% | +16% | no figures |
|
› |
| 11 Aug Q1FY24 | — | unread | -3.5% | -6.1% | -5.7% | +30% | no figures |
|
› |
| 31 May Q4FY23 | — | unread | +3.9% | +6.9% | +6.5% | +4% | no figures |
|
› |
| 13 Feb Q3FY23 | — | unread | +4.1% | +2.1% | +4.7% | +13% | no figures |
|
› |
| 15 Nov Q2FY23 | — | unread | +1.8% | +8.1% | +6.1% | +14% | no figures |
|
› |
| 14 Aug Q1FY23 | — | unread | +5.6% | +4.8% | +4.5% | +14% | no figures |
|
› |
| 31 May Q4FY22 | — | unread | +0.7% | -3.7% | +1.6% | -18% | no figures |
|
› |
| 11 Feb Q3FY22 | — | unread | -6.7% | -12.5% | -9.1% | -9% | no figures |
|
› |
| 10 Nov Q2FY22 | — | unread | -9.4% | -15.1% | -12.3% | -2% | no figures |
|
› |
| 11 Aug Q1FY22 | — | unread | +2.2% | -6.2% | -8.4% | -12% | no figures |
|
› |
| 31 May Q4FY21 | — | unread | -1.4% | +20.3% | +18.5% | +37% | no figures |
|
› |
| 8 Feb Q3FY21 | — | unread | -6.0% | -12.1% | -9.4% | — | no figures |
|
› |
| 6 Nov Q2FY21 | — | unread | -5.3% | +16.9% | +11.5% | +9% | no figures |
|
› |
| 4 Aug Q1FY21 | — | unread | +10.1% | +25.2% | +22.4% | +17% | no figures |
|
› |